...Di Meng; Lei Zhao; Jinyang Liu; Chunlin Ge; Cheng Zhang Introduction: Most patients with pancreatic neuroendocrine tumors (pNETs) present with unresectable or metastatic disease. Increasing evidence shows that the immune cell infiltration patterns play a pivotal role in tumor progression in pNETs...

...Yiying Guo; Chao Tian; Zixuan Cheng; Ruao Chen; Yuanliang Li; Fei Su; Yanfen Shi; Huangying Tan Introduction: Treatment response to the standard therapy is low for metastatic pancreatic neuroendocrine tumors (PanNETs) mainly due to the tumor heterogeneity. We investigated the heterogeneity between...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Streptozotocin Pancreatic neuroendocrine tumors Historical review On May 7, 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin (STZ...

...Fayez Awwad; Ann-Kathrin Ozga; Tania Amin; Catarina Schlueter; Sajeda Kailani; Daniel Perez; Stefan Wolter; Guido Sauter; Jakob Izbicki; Ansgar Wilhelm Lohse; Joerg Schrader Introduction: Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of neoplasms. Surgery is the only curative...

... in pancreatic neuroendocrine tumors (PanNETs). This study evaluated whether this association is applicable to Chinese patients as well as the potential somatic mutations associated with ALT. Methods: We assessed the prevalence of ALT by performing telomere-specific fluorescence in situ hybridization...

...-free DNA Droplet digital PCR Small intestinal neuroendocrine tumors Pancreatic neuroendocrine tumors Prognosis Peptide receptor radionuclide therapy Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors arising from neuroendocrine cells in the diffuse neuroendocrine system...

... of pancreatic neuroendocrine tumors (PNETs), allowing repeat monitoring examinations in multiple endocrine neoplasia type 1 (MEN-1) patients. Objectives: We aimed to compare the diagnostic accuracy of conventional MRI sequences to identify which sequence better depicts the presence of PNETs in MEN-1 patients...

...Marina Tatura; Harald Schmidt; Mikail Haijat; Maren Stark; Anja Rinke; Ramona Diels; Rita T. Lawlor; Aldo Scarpa; Joerg Schrader; Thilo Hackert; Simon Schimmack; Thomas Matthias Gress; Malte Buchholz Background/Aims: Many aspects of the biology of pancreatic neuroendocrine tumors (PanNETs...

... Oxaliplatin Pancreatic neuroendocrine tumors Gastroenteropancreatic neuroendocrine tumors Neuroendocrine tumors (NETs) usually present as advanced, nonfunctioning and low/ intermediate grade of malignancy, and only in a minority of cases as high grade [ 1 ]. Though many NETs are clinically silent...

...Phillip G. Claringbold; J. Harvey Turner Background/Methods: Thirty patients with advanced progressive grade 1 or 2 pancreatic neuroendocrine tumors (pNETs), treated on a prospective phase II single-center study, were followed up for up to 4 years after 4 cycles of 7.9 GBq 177 Lu-octreotate...

... a significantly lower incidence of bilobar LM compared with those in the palliative resection group and the no resection group (50 vs. 81 vs. 95%, p < 0.0001). Pancreatic neuroendocrine tumors (PNET) are relatively rare neoplasms. However, there has been a steady increase in their incidence and prevalence...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pancreatic neuroendocrine tumors LINE-1 hypomethylation DNA hypermethylation Copy number alterations Pancreatic...

...) in patients with advanced G1-G2 pancreatic neuroendocrine tumors. Patients and Methods: Fifty-two consecutive patients were treated at two different therapeutic dosages of 18.5 or 27.8 GBq in five cycles, according to the patient's kidney function and bone marrow reserve, which are known to be the critical...

...Bertram Wiedenmann; Marianne Pavel; Beata Kos-Kudla Pancreatic neuroendocrine tumors (pancreatic NET) are relatively rare, slowly growing tumors, although their incidence is increasing, and patients may survive for several years with metastatic disease. Apart from symptomatic relief, there have...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pancreatic endocrine tumors Pancreatic neuroendocrine tumors Islet cell tumors Radiation Chemoradiation Chemoradiotherapy Pancreatic...